AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05435443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerBreathe and PEP Therosold tools
Description: Initially, the following data were collected from each subject in addition to basic epidemiological data:~M-mode diaphragmatic excursion measurements, both in inspiration and expiration via ultrasound; spirometry is also carried out, obtaining values of forced vital capacity (FVC or FVC), forced expiratory volume (FEV), portion of FVC (FEV1/FVC), peak expiratory flow (PEF), mean expiratory flow, peak inspiratory pressure (PIM) and peak expiratory pressure (PEM). A 30-day treatment plan was carried out in which one group (Tool Group) had to perform 5 minutes of exercise with each tool, alternating with one minute of rest between each minute of exercise, starting with the Therosold PEP® and then the PowerBreathe®. The resistances applied to the devices were marked according to the specific assessment of each subject, in relation to the spirometric values of PIM and PEM.
Study NCT05844488 — intervention group
Intervention type: DEVICE
Intervention: PrecivityAD
Description: Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
Study NCT04579939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Candy Glucose Tolerance Test
Description: Participants will use a popular dextrose candy alternative to help assess glycemic response.
Study NCT05097040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy (ACT)
Description: The intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 6 weeks through Zoom videoconferencing. Also, a one-time 1-hour booster session will be provided at 1-month follow-up to facilitate the maintenance of treatment effects.
Study NCT06293651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4505
Description: Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
Study NCT06293651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4505 + Pembrolizumab
Description: Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
Study NCT04980144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
Study NCT04980144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% hyaluronate
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Study NCT06050824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparing Load and Concomitant therapy
Description: Levofloxacin - Omeprazole - nitazoxanide - doxycycline
Study NCT04392180 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview
Description: There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
Study NCT04823299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: Cryoballoon pulmonary vein isolation ablation
Study NCT04823299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation +EPS guided trigger and substrate ablation
Description: RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
Study NCT05053165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-P6
Description: Healthy subjects will be randomized to receive LB-P6 once daily orally
Study NCT05053165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-P8
Description: Healthy subjects will be randomized to receive LB-P8 once daily orally
Study NCT05053165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthy subjects will be randomized to receive placebo once daily orally
Study NCT04991779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AI-assisted cEEG detection tool
Description: This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool.~The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction.~The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association.
Study NCT04894747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bolus ingestion of protein
Description: Ingestion of 25g of protein
Study NCT05090657 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation
Description: After topical application photosensitive solution bilateral nasal light diffusers will be inserted into each nostril and two 2-minute non-thermal light applications of 670 nm light will be used to activate the photosensitizer to achieve an oxidative burst to destroy pathogens.
Study NCT05417425 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant
Description: The three omeza products were designed to be used in combination for the treatment of chronic wounds
Study NCT05833386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral access sheath placement during flexible ureteroscope for renal stones
Description: Ureteral access sheath placement during flexible ureteroscope
Study NCT06021821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoundMind App
Description: he SoundMind application uses binaural beats to encourage relaxation, focus, and alertness.
Study NCT06021821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spotify Playlist
Description: Participants will listen to a calm vibes playlist by Spotify.
Study NCT06150326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical honey Activon® 25g Tube
Description: no blinding procedures will be set up for the adminisration of the treatement
Study NCT06150326 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: no blinding procedures will be set up for the adminisration of the treatement
Study NCT06202716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab plus CapeOX chemotherapy
Description: Cadonilimab plus oxaliplatin/capecitabine (CapeOX) chemotherapy as first-line treatment in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma: Cadonilimab 10mg/kg, iv, q3w + oxaliplatin 130mg/m2, vd, d1 + capecitabine 1000mg/m2, po, bid, d1-d4, q3w (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
Study NCT04806308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otolaryngology stretching micro-breaks (OSMB)
Description: Standardized microbreak stretch that is designed to perform intraoperatively within the sterile field at medically convenient 20-40 min intervals throughout each procedure.
Study NCT04548453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uterine electromyography
Description: Multichannel uterine electromyography will record uterine biosignals during labor.
Study NCT05571878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog
Description: All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
Study NCT05571878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
Study NCT04700826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants
Description: choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice
Study NCT04853459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Border modeling..Measurement
Description: By using light cure to make border modeling in complete denture.
Study NCT03884166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: bronchoscopy
Description: Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
Study NCT06114706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physicians assess patients
Description: Physicians are asked to assess patients following the current Swedish guideline
Study NCT06114706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurses assess patients
Description: Nurses are asked to assess patients following the current Swedish guideline
Study NCT06114706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacists assess patients
Description: Pharmacists are asked to assess patients following the current Swedish guideline
Study NCT05265806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
Study NCT05265806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral oxytocin
Description: Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
Study NCT05265806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical amount of intranasal administration of placebo (identical ingredients except the peptide - i.e. glycerine and sodium chloride) will be assigned to each subject.
Study NCT04768179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
Description: Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days
Study NCT05007795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Targeted sequencing using the GenoScreen Deeplex assay
Description: Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.
Study NCT05719090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
Study NCT05915702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study NCT05915702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study NCT05915702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study NCT05915702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study NCT05451030 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: remote ischemic preconditioning
Description: The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
Study NCT05451030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: The cuff of a pneumatic electronic auto-control device placed around the bilateral upper limbs was used to deliver the protocol: 5 cycles of cuff inflation (200mmHg for 5 minutes) and deflation (for 5 minutes), for a total procedure time of 50 minutes, twice daily from the first DSA to the day of carotid artery stenting.
Study NCT05067647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENSEAL X1 Curved Jaw Tissue Sealer
Description: ENSEAL X1 curved jaw tissue sealer is used for transecting and sealing vessels during thoracic, urologic, or ENT procedures according to instructions for use.
Study NCT05939180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.
Study NCT05939180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.
Study NCT05669768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib/Tamoxifen
Description: Pamiparib 40mg PO BID, Tamoxifen 20mg PO BID
Study NCT05184842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg po on days 1, 8, 15 and 28 of each cycle (28day cycle)
Study NCT05184842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
Study NCT05354232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 2mA condition, the investigators will assist the administration of a 2mA current stimulation from the device.
Study NCT05354232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 mA transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the 1mA condition, the investigators will assist the administration of a 1mA current stimulation from the device.
Study NCT05354232 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: tDCS is a non-invasive neuromodulatory technique that has previously demonstrated the ability to transiently modulate cognitive domains in both healthy and psychiatric populations. In the sham condition, the investigators will assist the administration of a sham stimulation from the device.
Study NCT05064462 — intervention group
Intervention type: OTHER
Intervention: Collection of EDTA blood sample (5 to 7 ml)
Description: For all the patients included in the study, the samples to measure the viral load will be taken during the transplantation, then at each of the consultations planned as part of the usual care during the first year post-transplant (at minimum once and maximum twice a month).~These samples will be taken at the same time as those taken as part of standard care.
Study NCT03734497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Carotis FTc 500 ml Ringer's lactate Lafleks®
Description: will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder
Study NCT03734497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Preloading 10 ml/kg Ringer's lactate Lafleks®
Description: will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading
Study NCT03734497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Control 2 ml/kg Ringer's lactate Lafleks®
Description: will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia
Study NCT05488548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP31670
Description: EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
Study NCT06353061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients randomized to the metformin group will start taking metformin within 1 day after group allocation. They will take one tablet of metformin (850 mg) once daily for three consecutive days. Subsequently, they will take metformin orally twice daily throughout the entire external and internal irradiation period, with each administration consisting of one tablet.
Study NCT06353061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The study requires all subjects to sequentially undergo external beam radiotherapy (EBRT) and intracavitary brachytherapy (BT). All radiotherapy must be completed within 7-8 weeks after treatment initiation. The total prescribed dose EQD2 for EBRT combined with BT should be ≥80 Gy; for subjects with squamous carcinoma with lesions ≤4 cm, the HR-CTV D90 should be ≥80 Gy; for subjects with adenocarcinoma or lesions >4 cm, it is recommended that HR-CTV D90 should be ≥85 Gy. When the prescribed dose is limited by organs at risk (OAR), priority should be given to covering HR-CTV. The radiotherapy plan in this study is based on image guidance. Imaging scans can use MRI or CT, and the scanning area should extend at least 5 cm above and below the PTV.
Study NCT06353061 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: The study requires all subjects to sequentially undergo external beam radiotherapy (EBRT) and intracavitary brachytherapy (BT). All radiotherapy must be completed within 7-8 weeks after treatment initiation. The total prescribed dose EQD2 for EBRT combined with BT should be ≥80 Gy; for subjects with squamous carcinoma with lesions ≤4 cm, the HR-CTV D90 should be ≥80 Gy; for subjects with adenocarcinoma or lesions >4 cm, it is recommended that HR-CTV D90 should be ≥85 Gy. When the prescribed dose is limited by organs at risk (OAR), priority should be given to covering HR-CTV. The radiotherapy plan in this study is based on image guidance. Imaging scans can use MRI or CT, and the scanning area should extend at least 5 cm above and below the PTV.
Study NCT06353061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
Study NCT06353061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
Study NCT06353061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Using 68Ga-NY104 as a small molecule targeted imaging agent for CA-IX, two CA-IX PET/CT scans will be conducted in patients: one upon enrollment and another one week after randomization.
Study NCT06353061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: Using 68Ga-NY104 as a small molecule targeted imaging agent for CA-IX, two CA-IX PET/CT scans will be conducted in patients: one upon enrollment and another one week after randomization.
Study NCT05602194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05602194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05602194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Given standard of care calaspargase pegol
Study NCT05602194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calaspargase Pegol
Description: Given standard of care calaspargase pegol
Study NCT05602194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Given PO or IV
Study NCT05602194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given standard of care pegaspargase
Study NCT05602194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given standard of care pegaspargase
Study NCT05602194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05602194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06181240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy
Description: Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
Study NCT05567614 — intervention group
Intervention type: RADIATION
Intervention: Liver Fibroscan
Description: Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis